Table 3.
Univariable and multivariable cox regression analysis for predicting sustained ventricular arrhythmia
| Variables | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95%CI) | P-Value | HR (95%CI) | P-Value | |
| Age (years) | 1.02(1.00–1.05) | 0.054 | ||
| Male, n (%) | 1.48(0.73–3.00) | 0.28 | ||
| BSA (m2) | 0.43(0.08–2.50) | 0.43 | ||
| Systemic hypertension, n (%) | 1.05(0.47–2.34) | 0.90 | ||
| Diabetes, n (%) | 1.40(0.49–3.96) | 0.54 | ||
| History of syncope, n (%) | 1.59(0.77–3.29) | 0.21 | ||
| Family history of CAD, n (%) | 1.74(0.53–5.75) | 0.36 | ||
| Proband, n (%) | 1.99(0.96–4.09) | 0.06 | ||
| NYHA III - IV, n (%) | 2.00(0.98–4.08) | 0.06 | ||
| NSVT, n (%) | 2.00(0.96–4.20) | 0.07 | ||
| 24-h PVC count (≥ 1000), n (%) | 2.61(1.07–6.32) | 0.034 | 1.31(0.45–3.82) | 0.62 |
| Inverted T-wave, n | 1.22(1.06–1.40) | 0.005 | 1.21(1.04–1.44) | 0.006 |
| Genotype, PKP2 | 1.50(0.68–3.31) | 0.32 | ||
| 5-yr ARVC risk score, (%) | 1.07(1.03–1.11) | 0.001 | 1.05(1.00-1.09) | 0.034 |
| CMR findings | ||||
| LV EDVi (mL/m2) | 1.01(0.98–1.03) | 0.65 | ||
| LV ESVi (mL/m2) | 1.03(1.01–1.05) | 0.047 | ||
| LV MI (g/m2) | 1.02(0.99–1.05) | 0.16 | ||
| LV EF (%) | 0.95(0.91–0.99) | 0.031 | 0.97(0.92–1.02) | 0.19 |
| LV RWMA, n (%) | 1.52(0.76–3.06) | 0.24 | ||
| LV fat infiltration, n (%) | 1.37(0.70–2.69) | 0.36 | ||
| LV LGE extent (%) | 1.05(1.02–1.08) | 0.013 | 1.03(0.99–1.06) | 0.07 |
| LV LGE pattern, n (%) | ||||
| No LGE | Ref. | Ref. | ||
| Non-ringlike LGE | 3.31(0.42–25.50) | 0.26 | 1.53(0.61–14.8) | 0.64 |
| Ringlike LGE | 11.24(1.51–84.37) | 0.001 | 6.91(1.89–54.60) | 0.036 |
| RV EDVi (mL/m2) | 1.01(0.99–1.02) | 0.15 | ||
| RV ESVi (mL/m2) | 1.02(0.99–1.03) | 0.11 | ||
| RV EF (%) | 0.94(0.88–1.001) | 0.052 | ||
| RV RWMA, n (%) | 1.77(0.89–3.54) | 0.11 | ||
| RV fat infiltration, n (%) | 1.94(0.99–3.82) | 0.054 | ||
| RV LGE, n (%) | 1.82(0.91–3.64) | 0.09 | ||
Values in bold indicate P < 0.05
HR hazard ratio, CI confidence interval, BSA body surface area, CAD coronary artery disease, NYHA New York Heart Association, NSVT non-sustained ventricular tachycardia, PVC premature ventricular complex, PKP2 plakophilin-2, ARVC arrhythmogenic right ventricular cardiomyopathy, LV left ventricular, EDVi end diastolic volume index, ESVi end systolic volume index, MI mass index, EF ejection fraction, RWMA regional wall motion abnormalities, LGE late gadolinium enhancement, RV right ventricular